Chemical linkers in antibody-drug conjugates (ADCs) / edited by Floris van Delft and John M. Lambert.
2022
RS201.A56
Formats
| Format | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS |
Linked e-resources
Details
Title
Chemical linkers in antibody-drug conjugates (ADCs) / edited by Floris van Delft and John M. Lambert.
ISBN
9781839165160 (electronic bk.)
1839165162 (electronic bk.)
9781839162633 (hbk.)
1839162635 (hbk.)
1839165162 (electronic bk.)
9781839162633 (hbk.)
1839162635 (hbk.)
Published
Cambridge : Royal Society of Chemistry, [2022]
Copyright
©2022
Language
English
Description
1 online resource (xvi, 460 pages)
Call Number
RS201.A56
System Control No.
(OCoLC)1289370803
Summary
The covalent conjugation of potent cytotoxic agents to monoclonal antibodies, known as antibody-drug conjugates (ADCs) is a powerful approach in the field of targeted treatment of cancer. Clearly, both monoclonal antibody and cytotoxic payload are crucial elements in determining the clinical value of an ADC and have receive ample attention. However, the structural element connecting the two –the chemical linker– also plays an essential role in mode-of-action, efficacy, pharmacokinetics and safety profile of an ADC, but is often underappreciated in considerations of ADC design.Chemical Linkers in Antibody–Drug Conjugates aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody ratio, for stability, for release mechanism of payload, for pharmacokinetics, for stability determination, and for efficacy and safety. Ideal for postgraduate students and active researchers in drug discovery and development, this book provides a comprehensive description of linkers used in ADCs (clinical and late preclinical), insight into key quality attributes of linkers for ADCs, and aids the reader in understanding the role of linker chemistry and designing new ADCs.
Bibliography, etc. Note
Includes bibliographical references and index
Formatted Contents Note
Introduction to antibody-drug conjugates / John M. Lambert and F. L. van Delft
Antibody conjugation technologies / G. T. Hermanson and F. L. van Delft
Linker design and impact on ADC properties / M. Frigerio and N. Camper
Non-cleavable linkers: permanently linked, for better or for worse / Julien Dugal-Tessier and Nareshkumar Jain
Protease-sensitive linkers / S. Johannes, A. Sommer and H.-G. Lerchen
Acid-labile linkers / E. A. Savoy, F. P. Olatunji, H. Yoon, N. Mesbahi, J. R. Knight and C. E. Berkman
ADC linkers strategies for the release of alcohol-containing payloads / Jared T. Miller and L. Nathan Tumey
Click-cleavable ADC linkers / R. Rossin and M. S. Robillard
The use of uniform PEG compounds in the design of ADCs / M. W. Giese, R. H. Woodman, G. T. Hermanson and P. D. Davis
Enhancing the polarity of the linker-drug in ADCs / Jorin Hoogenboom and Sander S. van Berkel
Trastuzumab deruxtecan targeting HER2-expressing cancers with a Dxd-ADC system consisting of a novel protease-sensitive linker and DNA topoisomerase I inhibitor with a hydroxyl group / Takashi Nakada, Yuki Abe and Toshinori Agatsuma
Antibody conjugation technologies / G. T. Hermanson and F. L. van Delft
Linker design and impact on ADC properties / M. Frigerio and N. Camper
Non-cleavable linkers: permanently linked, for better or for worse / Julien Dugal-Tessier and Nareshkumar Jain
Protease-sensitive linkers / S. Johannes, A. Sommer and H.-G. Lerchen
Acid-labile linkers / E. A. Savoy, F. P. Olatunji, H. Yoon, N. Mesbahi, J. R. Knight and C. E. Berkman
ADC linkers strategies for the release of alcohol-containing payloads / Jared T. Miller and L. Nathan Tumey
Click-cleavable ADC linkers / R. Rossin and M. S. Robillard
The use of uniform PEG compounds in the design of ADCs / M. W. Giese, R. H. Woodman, G. T. Hermanson and P. D. Davis
Enhancing the polarity of the linker-drug in ADCs / Jorin Hoogenboom and Sander S. van Berkel
Trastuzumab deruxtecan targeting HER2-expressing cancers with a Dxd-ADC system consisting of a novel protease-sensitive linker and DNA topoisomerase I inhibitor with a hydroxyl group / Takashi Nakada, Yuki Abe and Toshinori Agatsuma
Series
ISSN.
Available in Other Form
Print version: Chemical linkers in antibody-drug conjugates (ADCs). Cambridge : Royal Society of Chemistry, 2021
Linked Resources
Record Appears in